Data On One-Year BRAVO Study of OviTex® Reinforced BioScaffolds for Ventral Hernia Repair


One-year data from TELA Bio®, Inc. post-market BRAVO Study (BioScaffold Reconstruction of Abdominal wall and Ventral hernia defects with Open or laparoscopic repair) study evaluating OviTex® Reinforced BioScaffolds for the treatment of ventral hernias are being presented at the 11th Annual Abdominal Wall Reconstruction Conference taking place June 6-8, 2019 in Washington, D.C.

In one poster presentation, titled, “Reinforced Biologic Reduces Risk of Recurrence in Ventral Hernia (VHR) Patients: One-Year Data from the BRAVO Ventral Hernia Study,” principal investigator George DeNoto III, MD, FACS, director of general surgery at St. Francis Hospital in New York, provided one-year results in the first 32 treated patients evaluated at 12 months post-surgery. No patient has had a hernia recurrence despite 80 percent of patients having one or more factors known to increase the risk of recurrence. Eight patients experienced a surgical site occurrence (SSO). None of these required surgical intervention or implant removal, and healing progressed uninterrupted.

“This analysis shows a lower recurrence rate than those reported in other prospective series,” said Dr. DeNoto. “The biomechanical optimization of the repair allowed by the reinforced biologic and its observed resilience against the effects of infection may both contribute to this observation. We look forward to longer follow-up in these and subsequent patients to confirm these findings.”

A second poster presentation, titled, “Initial Experience with Reinforced Biologics in Minimally Invasive Ventral Hernia Repair (MIVHR),” reports surgeon experience with OviTex Reinforced BioScaffolds in both open and MIVHR. Among the 26 patients with MIVHR, 100% of surgeons cited OviTex as being easy to place and the average surgeon satisfaction at 30 and 90 days was 9.69/10 and 9.67/10, respectively.

“We are pleased to present updated results from our ongoing BRAVO study and are committed to collecting longer-term data on the use of OviTex Reinforced BioScaffolds to support improved patient care and address the needs of surgeons and healthcare systems,” said Maarten Persenaire, M.D., chief medical officer of TELA Bio. “The data continues to show that OviTex products are easy to use in a range of procedures and techniques, including robotic and laparoscopic procedures, and we are especially encouraged by the lack of recurrences seen so far after one year.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version